FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileSpyGlass Pharma, Inc. Common Stock
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
SGP
SpyGlass Pharma, Inc. Common Stock Stock AnalysisComprehensive stock analysis for SpyGlass Pharma, Inc. Common Stock (SGP) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisSGP
SGP
SpyGlass Pharma, Inc. Common Stock
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
SGP
  1. Home
  2. Stocks
  3. SpyGlass Pharma, Inc. Common Stock

SpyGlass Pharma, Inc. Common Stock

🇺🇸SGP•NASDAQ

SpyGlass Pharma, Inc. Common Stock

🇺🇸SGP•NASDAQ
Market cap
$1.02B

Your view on SGP

Mkt Cap
$1.02B
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About SpyGlass Pharma, Inc. Common Stock

Industry
Biotechnology
Sector
Healthcare
CEO
Patrick H. Mooney
Headquarters
27061 Aliso Creek Road, Aliso Viejo, CA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Patrick H. Mooney
Headquarters
27061 Aliso Creek Road, Aliso Viejo, CA, US
Description

SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions.

Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT).

Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for SpyGlass Pharma, Inc. Common Stock. Starting points for SpyGlass Pharma, Inc. Common Stock: EPS -$2.11, beta -0.89 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for SpyGlass Pharma, Inc. Common Stock. Trailing twelve-month EPS for SpyGlass Pharma, Inc. Common Stock stands at -$2.11. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for SpyGlass Pharma, Inc. Common Stock. SpyGlass Pharma, Inc. Common Stock has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold SGP12 companies
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
FAMDFFutura Medical plcHealthcareOTC$6.1M
FATEFate Therapeutics, Inc.HealthcareNASDAQ$107.1M
FBIOFortress Biotech, Inc.HealthcareNASDAQ$63.4M
FBIOPFortress Biotech, Inc.HealthcareNASDAQ$56.0M
FBLGFibroBiologics, Inc. Common StockHealthcareNASDAQ$6.3M
FDMT4D Molecular Therapeutics, Inc.HealthcareNASDAQ$576.8M
FENCFennec Pharmaceuticals Inc.HealthcareNASDAQ$462.1M
FGHQFFrontage Holdings CorporationHealthcareOTC$283.9M
FHTXFoghorn Therapeutics Inc.HealthcareNASDAQ$103.1M
FLNAFilana Therapeutics, Inc.HealthcareNASDAQ$31.0M
FNAMEvolutionary Genomics, Inc.HealthcareOTC$1,331
FNCHQFinch Therapeutics Group, Inc.HealthcareOTC—
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold SpyGlass Pharma, Inc. Common Stock, and how their positions are changing. At a $1.02B market value, institutional positions materially move SpyGlass Pharma, Inc. Common Stock's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for SpyGlass Pharma, Inc. Common Stock. Coverage tracks SpyGlass Pharma, Inc. Common Stock within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of SpyGlass Pharma, Inc. Common Stock.

SGP AnalysisFair
Past
3
Growth
2
Health
5
Profit
1
Value
1